- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Sattva S. Neelapu, MD | Authors
Articles
Key Takeaway From 2-Year Follow-Up Data of ZUMA-1 Trial in Large B-Cell Lymphoma
December 17, 2018
Video
Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.
Long-Term Follow-Up Results From the ZUMA-1 Trial in Non-Hodgkin Lymphoma
February 23, 2018
Video
Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses long-term findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory aggressive non-Hodgkin lymphoma.
Design of the ZUMA-1 Trial in Non-Hodgkin Lymphoma
August 23, 2017
Video
Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial in non-Hodgkin lymphoma.
Results of the ZUMA-1 Trial Exploring KTE-C19 in NHL
May 19, 2017
Video
Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.